Hope for rare disorder: Two-Year drug trial tests weight and hormone benefits
NCT ID NCT04240821
Summary
This study is testing the long-term safety and effects of a drug called theophylline in people with a rare genetic disorder called pseudohypoparathyroidism. It involves about 34 children and young adults who have already completed a previous related trial. The main goals are to see if the drug is safe to take for two years and if it helps with weight, blood sugar, and hormone problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSEUDOHYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
Conditions
Explore the condition pages connected to this study.